Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Oncology and

Expert Opinion / Interview · July 28, 2016

Role of VEGF/TKIs in Priming Tumors for Checkpoint Inhibitors in RCC: Sequencing Implications

Interview by: Farzanna S Haffizulla MD, FACP, FAMWA
Interview with: Eric Jonasch MD; Neeraj Agarwal MD; Sumanta Kumar Pal MD; Tanya B Dorff MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Pal SK, Hossain S, Zhang O, et al. Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile. J Urol; 2015;193(4):1114-1121.

Disclosure statements are available on the authors' profiles:

Neeraj Agarwal MD

Eric Jonasch MD

Sumanta Pal MD

featured

MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL: Long-Term Efficacy and ctDNA Analysis

Blood · May 02, 2024
featured

Cadonilimab Plus Chemotherapy With or Without Bevacizumab as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer

Clin. Cancer Res · May 01, 2024
featured

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

J. Clin. Oncol · May 01, 2024
story of the week

Laparoscopic vs Open Hemihepatectomy in Patients With Primary or Metastatic Cancer

J. Clin. Oncol · April 30, 2024
featured

Development and Validation of an 18-Gene Urinary Test for High-Grade Prostate Cancer

JAMA Oncol · April 30, 2024
story of the week

Remission Induction vs Immediate Allogeneic HSCT for Relapsed or Poorly Responsive AML

Lancet Haematol · April 25, 2024

updated
featured

Association of Prostate-Specific Antigen Screening With 15-Year Prostate Cancer Mortality

JAMA · April 25, 2024
featured

Tissue-Specific Thresholds of Mutation Burden Associated With Anti–PD-1/Anti–PD-L1 Therapy Benefit and Prognosis in Microsatellite-Stable Cancers

Nat Cancer · April 24, 2024

updated
featured

Early Incorporation of Palliative Care in Patients With Advanced NSCLC

Oncologist · April 24, 2024
story of the week

Alectinib for Resected ALK-Positive NSCLC

N. Engl. J. Med · April 23, 2024
featured

Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

Lancet · April 18, 2024

Renal Cell Carcinoma

Role of VEGF/TKIs in Priming Tumors for Checkpoint Inhibitors in RCC: Sequencing Implications

Additional Info

Further Reading

MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL: Long-Term Efficacy and ctDNA Analysis

Cadonilimab Plus Chemotherapy With or Without Bevacizumab as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer

Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

Laparoscopic vs Open Hemihepatectomy in Patients With Primary or Metastatic Cancer

Development and Validation of an 18-Gene Urinary Test for High-Grade Prostate Cancer

Remission Induction vs Immediate Allogeneic HSCT for Relapsed or Poorly Responsive AML

Association of Prostate-Specific Antigen Screening With 15-Year Prostate Cancer Mortality

Tissue-Specific Thresholds of Mutation Burden Associated With Anti–PD-1/Anti–PD-L1 Therapy Benefit and Prognosis in Microsatellite-Stable Cancers

Early Incorporation of Palliative Care in Patients With Advanced NSCLC

Alectinib for Resected ALK-Positive NSCLC

Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

Related Videos